Skip to main content
Top
Published in: BMC Geriatrics 1/2023

Open Access 01-12-2023 | Statins | Research article

Effect of statin treatment on mortality in elderly patients with type 2 diabetes mellitus patients: a retrospective cohort study

Authors: Yao Fan, Juan Wang, Haidi Wu, Lingli Dai, Lan Wang, Liubao Gu

Published in: BMC Geriatrics | Issue 1/2023

Login to get access

Abstract

Background

The effects of statins on the reduction of mortality in individuals aged 75 years or older remain controversial. We conducted this study to investigate whether there is an association between statin therapy and mortality in patients with type 2 diabetes mellitus (T2DM) who are over the age of 75 years.

Methods

The present study used data from the Staged Diabetes Targeting Management Study, which began in 2005. A total of 518 T2DM patients older than 75 years were included. Cox regression analyses were used to evaluate the association between statins and specific causes of death in patients with T2DM.

Results

After a follow-up period of 6.09 years (interquartile range 3.94–8.81 years), 111 out of 518 patients died. The results of Cox regression analyses showed that there was no significant association between statin use and all-cause mortality (HR 0.75; 95% CI 0.47, 1.19) after adjustment for all potential confounders. Subgroup analysis indicated that statins had no association with the risk of all-cause mortality or deaths caused by ischemic cardiovascular diseases in T2DM patients with or without coronary heart disease.

Conclusions

Our study found no significant association between all-cause mortality and statin use in T2DM patients over the age of 75 years. More evidence is needed to support the use of statins in the elderly T2DM patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Marrugat J, Sala J, Manresa JM, Gil M, Elosua R, Perez G, et al. Acute myocardial infarction population incidence and in-hospital management factors associated to 28-day case-fatality in the 65 year and older. Eur J Epidemiol. 2004;19(3):231–7.CrossRefPubMed Marrugat J, Sala J, Manresa JM, Gil M, Elosua R, Perez G, et al. Acute myocardial infarction population incidence and in-hospital management factors associated to 28-day case-fatality in the 65 year and older. Eur J Epidemiol. 2004;19(3):231–7.CrossRefPubMed
2.
go back to reference Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–210.CrossRef Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–210.CrossRef
3.
go back to reference Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMed Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMed
4.
go back to reference Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.CrossRef Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.CrossRef
6.
go back to reference Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl. 2006;7(1):31–5.CrossRefPubMed Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl. 2006;7(1):31–5.CrossRefPubMed
7.
go back to reference Yandrapalli S, Gupta S, Andries G, Cooper HA, Aronow WS. Drug therapy of dyslipidemia in the elderly. Drugs Aging. 2019;36(4):321–40.CrossRefPubMed Yandrapalli S, Gupta S, Andries G, Cooper HA, Aronow WS. Drug therapy of dyslipidemia in the elderly. Drugs Aging. 2019;36(4):321–40.CrossRefPubMed
8.
go back to reference Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71(1):85–94.CrossRefPubMed Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71(1):85–94.CrossRefPubMed
9.
go back to reference Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33–40.CrossRefPubMed Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33–40.CrossRefPubMed
10.
go back to reference Singh S, Zieman S, Go AS, Fortmann SP, Wenger NK, Fleg JL, et al. Statins for primary prevention in older adults-moving toward evidence-based decision-making. J Am Geriatr Soc. 2018;66(11):2188–96.CrossRefPubMedPubMedCentral Singh S, Zieman S, Go AS, Fortmann SP, Wenger NK, Fleg JL, et al. Statins for primary prevention in older adults-moving toward evidence-based decision-making. J Am Geriatr Soc. 2018;66(11):2188–96.CrossRefPubMedPubMedCentral
11.
go back to reference Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PloS one. 2012;7(3):e33559.CrossRefPubMedPubMedCentral Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PloS one. 2012;7(3):e33559.CrossRefPubMedPubMedCentral
12.
go back to reference Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Statin use for the primary prevention of cardiovascular disease in adults: us preventive services task force recommendation statement. Jama. 2016;316(19):1997–2007.CrossRef Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Statin use for the primary prevention of cardiovascular disease in adults: us preventive services task force recommendation statement. Jama. 2016;316(19):1997–2007.CrossRef
13.
go back to reference Ramos R, Comas-Cufi M, Marti-Lluch R, Ballo E, Ponjoan A, Alves-Cabratosa L, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018;362:k3359.CrossRefPubMedPubMedCentral Ramos R, Comas-Cufi M, Marti-Lluch R, Ballo E, Ponjoan A, Alves-Cabratosa L, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018;362:k3359.CrossRefPubMedPubMedCentral
14.
go back to reference Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A. Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study. Am J Med. 2019;132(6):740–740-8 e7.CrossRefPubMed Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A. Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study. Am J Med. 2019;132(6):740–740-8 e7.CrossRefPubMed
15.
go back to reference Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–15.CrossRef Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–15.CrossRef
16.
go back to reference Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. 2016;31(4):387–93.CrossRefPubMed Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. 2016;31(4):387–93.CrossRefPubMed
17.
go back to reference Ouyang XMY, Bian R, et al. Improving glycemic control in T2DM patients: Implementation of staged diabetes targeting management. Chin J Diabetes. 2013;21:55–9. Ouyang XMY, Bian R, et al. Improving glycemic control in T2DM patients: Implementation of staged diabetes targeting management. Chin J Diabetes. 2013;21:55–9.
18.
go back to reference Bi Y, Liu L, Lu Y, Sun T, Shen C, Chen X, et al. T7 peptide-functionalized PEG-PLGA micelles loading with carmustine for targeting therapy of glioma. ACS Appl Mater Interfaces. 2016;8:27465–73.CrossRefPubMed Bi Y, Liu L, Lu Y, Sun T, Shen C, Chen X, et al. T7 peptide-functionalized PEG-PLGA micelles loading with carmustine for targeting therapy of glioma. ACS Appl Mater Interfaces. 2016;8:27465–73.CrossRefPubMed
19.
go back to reference Mazze RS, Etzwiler DD, Strock E, Peterson K, McClave CR 2nd, Meszaros JF, et al. Staged diabetes management. Toward an integrated model of diabetes care. Diabetes Care. 1994;17(Suppl 1):56–66.PubMed Mazze RS, Etzwiler DD, Strock E, Peterson K, McClave CR 2nd, Meszaros JF, et al. Staged diabetes management. Toward an integrated model of diabetes care. Diabetes Care. 1994;17(Suppl 1):56–66.PubMed
20.
go back to reference Li M, Gu L, Yang J, Lou Q. Serum uric acid to creatinine ratio correlates with beta-cell function in type 2 diabetes. Diabetes Metab Res Rev. 2018;34(5):e3001.CrossRefPubMed Li M, Gu L, Yang J, Lou Q. Serum uric acid to creatinine ratio correlates with beta-cell function in type 2 diabetes. Diabetes Metab Res Rev. 2018;34(5):e3001.CrossRefPubMed
21.
go back to reference Gu L, Huang L, Wu H, Lou Q, Bian R. Serum uric acid to creatinine ratio: a predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function. Diab Vasc Dis Res. 2017;14(3):221–5.CrossRefPubMed Gu L, Huang L, Wu H, Lou Q, Bian R. Serum uric acid to creatinine ratio: a predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function. Diab Vasc Dis Res. 2017;14(3):221–5.CrossRefPubMed
22.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral
23.
go back to reference Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–96, W174.CrossRefPubMedPubMedCentral Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–96, W174.CrossRefPubMedPubMedCentral
24.
go back to reference Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.CrossRefPubMed Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.CrossRefPubMed
25.
go back to reference Savarese G, Gotto AM Jr, Paolillo S, D’Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090–9.CrossRefPubMed Savarese G, Gotto AM Jr, Paolillo S, D’Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090–9.CrossRefPubMed
26.
go back to reference Teng M, Lin L, Zhao YJ, Khoo AL, Davis BR, Yong QW, et al. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis. Drugs Aging. 2015;32(8):649–61.CrossRefPubMed Teng M, Lin L, Zhao YJ, Khoo AL, Davis BR, Yong QW, et al. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis. Drugs Aging. 2015;32(8):649–61.CrossRefPubMed
27.
go back to reference Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177(7):955–65.CrossRefPubMedPubMedCentral Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177(7):955–65.CrossRefPubMedPubMedCentral
28.
go back to reference Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020;324(1):68–78.CrossRefPubMedPubMedCentral Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020;324(1):68–78.CrossRefPubMedPubMedCentral
29.
go back to reference Kim K, Lee CJ, Shim CY, Kim JS, Kim BK, Park S, et al. Statin and clinical outcomes of primary prevention in individuals aged >75years: The SCOPE-75 study. Atherosclerosis. 2019;284:31–6.CrossRefPubMed Kim K, Lee CJ, Shim CY, Kim JS, Kim BK, Park S, et al. Statin and clinical outcomes of primary prevention in individuals aged >75years: The SCOPE-75 study. Atherosclerosis. 2019;284:31–6.CrossRefPubMed
30.
go back to reference Olafsdottir E, Aspelund T, Sigurdsson G, Thorsson B, Eiriksdottir G, Harris TB, et al. Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study. BMJ Open. 2011;1(1):e000132.CrossRefPubMedPubMedCentral Olafsdottir E, Aspelund T, Sigurdsson G, Thorsson B, Eiriksdottir G, Harris TB, et al. Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study. BMJ Open. 2011;1(1):e000132.CrossRefPubMedPubMedCentral
31.
Metadata
Title
Effect of statin treatment on mortality in elderly patients with type 2 diabetes mellitus patients: a retrospective cohort study
Authors
Yao Fan
Juan Wang
Haidi Wu
Lingli Dai
Lan Wang
Liubao Gu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2023
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-023-04252-y

Other articles of this Issue 1/2023

BMC Geriatrics 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine